Mileutis

Mileutis is a bio-pharmaceutical company focused on the discovery, development, and commercialization of novel and biologically sourced, safe, and residual-free therapies for animal and human health. Mileutis has developed a line of biopharmaceuticals that are revolutionizing the way in which farmers and veterinarians treat a wide range of diseases. Mileutis’ first products are comprised of peptides and specific protein fragments that have a positive impact on body functions and conditions that influence health. These peptides act through an immune-modulatory effect, enabling the management of infectious and chronic diseases without the use of antibiotics, thereby reducing the use of antibiotics in animal and human healthcare. This will assist in overcoming the global threat of antimicrobial resistance (AMR) generated by, among other things, the overuse of antibiotics. The company's lead products are Imilac and Milac, which target the management, treatment, and prevention of mastitis in dairy cows. Mileutis's products aim to replace antibiotics in dairy farms, improve cow wellbeing, and provide additional and significant economic value to farmers by increasing milk yield and productivity.

Mileutis has raised $20M in total funding across 2 rounds. The company is currently at the Seed stage. Key investors include Yotvata Dairy, NovaQuest Capital Management.

Mileutis was founded in 2004 by David Javier Iscovich, MBA (Founder & CEO), Jose Iscovich, MD, MSc (Founder & President).

Mileutis operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Agriculture & Food, Livestock.

Mileutis is based in Golda Me'ir Street 7, Ness Ziona, Israel, Center District.